Revance reports Q4 EPS ($1.82), consensus (95c)

Reports Q4 revenue $49.9M, consensus $46.55M. "I’m very pleased with our outstanding performance in 2022, highlighted by the FDA’s approval of DAXXIFY in September which lays the foundation for our significant growth opportunity ahead. To that end, we are encouraged by the positive early feedback we’ve received on DAXXIFY during our PrevU program and look forward to initiating our commercial launch in late March with a focus on our existing practice partners," said Mark Foley, Chief Executive Officer. "During the course of 2022, we also took important steps to fortify our balance sheet, allowing us to launch DAXXIFY and grow our aesthetics franchise from a position of strength. 2023 will be another exciting and important year for the company as we introduce DAXXIFY and prepare for our entry into the therapeutics market."